Introduction
Breast cancer is a complex and heterogeneous disease at the molecular level. Treatment is efficient in only 70% of cases in spite of improvement in early diagnosis and therapies. Two major types of differentiated cells can be distinguished in the mammary epithelium. Ducts and lobules are lined by a luminal layer of secretory cells, whereas myoepithelial cells are in contact with the basement membrane. In addition, putative self-renewing pluripotent stem cells and committed progenitors have been identified. Progenitors occupy a basal (or rather suprabasal) position in the epithelium, between the myoepithelial and luminal layers. Several hierarchical branching models of differentiation have been proposed. In one model, self-renewing pluripotent stem cells give rise to two main lineages, luminal/glandular and myoepithelial-restricted (Stingl et al., 2001; Boecker and Buerger, 2003; Dontu et al., 2003; Birnbaum et al., 2004) .
A molecular taxonomy of breast cancers has been proposed that is closely associated with the differentiation model (Sorlie et al., 2001; Sorlie et al., 2003) . Using DNA microarrays, five subtypes have been identified (luminal A, luminal B, basal, . Luminal and basal-like breast cancers correspond to two distinct types of epithelial cells found in normal mammary gland (Perou et al., 2000) . These subtypes show a different clinical course (Sorlie et al., 2001; Sorlie et al., 2003) and response to therapeutic agents (Troester et al., 2004; Bertucci et al., 2005) . The molecular taxonomy has been confirmed by protein expression profiling (Abd El-Rehim et al., 2005; Jacquemier et al., 2005) . It should have profound impact on breast cancer management in helping adapt the treatment to specific, more homogeneous molecular subtypes.
A great part of our knowledge on breast carcinomas is based on in vivo and in vitro studies done on breast cell lines (BCL). They provide an unlimited and easily handled source of self-replicating material, free of contaminating stromal cells. They are representative models of the tumours they are derived from and powerful tools to test the efficiency of therapeutic drugs (Lacroix and Leclercq, 2004) . Conversely, BCL have limitations. They represent only clonal isolates, separated from their stromal environment; and their sustained growth in culture might modify the phenotype and lead to an accumulation of genome alterations.
However, the phenotypic and genotypic properties of cultured cell lines appear to remain similar for a very long time (Wistuba et al., 1998) . Curiously, even the most studied BCL remain poorly characterized (Lacroix and Leclercq, 2004) . Some BCL have been studied by DNA microarrays and classified in molecular subtypes (Perou et al., 2000; Ross and Perou, 2001) , revealing an additional 'mesenchymal subtype', which was not identified in tumour samples (Sorlie et al., 2003) .
Gene expression profile of a large series of BCL on a whole-genome scale remains to be established. Using DNA microarrays, we have determined here the molecular subtypes of 31 BCL. We have validated the subtypes at the protein level. Our aim was in particular to better define the basal subtype, which is not well characterized and has been associated with unfavourable clinical outcome.
Results

Gene expression profiling of breast cell lines
A total of 31 BCL were profiled using Affymetrix wholegenome oligonucleotide microarrays (all expression data are available in Supplementary Table 1) . Before analysis, a filter procedure eliminated genes with uniformly low expression or with low expression variation across the experiments, retaining 15 293 genes/ESTs. Results of hierarchical clustering are shown in Figure 1 . BCL displayed heterogeneous expression profiles, as reflected by the dendrogram branch length (Figure 1b) . Overall, they fell in two groups. Group I included only carcinoma cell lines, with the majority (11 cell lines) derived from ductal carcinoma (BT-474, BT-483, HCC1500, MCF-7, MDA-MB-134, MDA-MB-175, SK-BR-3, T47D, UACC . The histological type of the other cell lines of this group (CAMA-1, MDA-MB-453, S68) was not available. Group II comprised six ductal carcinoma cell lines (BT-20, HCC38, BRCA1-mutated HCC1937, HCC1954, SK-BR-7, and inflammatory breast SUM-149), mesenchymal-like MDA-MB-231 and carcinosarcoma Hs578T, two medullary BCL (MDA-MB-157 and BrCa-MZ-01), and three noncancerous BCL (184B5, MCF-10A, and HME-1). A strong correlation existed between the two groups and the oestrogen receptor (ER) status of cell lines, with more ER-positive cell lines in group I as compared with group II (P ¼ 0.036, Fisher's exact test).
Gene clustering revealed groups of coexpressed genes, some of which represented expression signatures corresponding to defined biological processes or cell types (see coloured bars on the right of Figure 1a and zooms in Figure 1c ). Two major clusters were prominent in the classification. One of them (1.160 genes, designated luminal cluster; blue bar in Figure 1a -c) included ESR1, which codes for ER-a, several transcription factor genes (GATA3, XBP1, PBX1, ZNF278, SPDEF) and genes associated with ER-positive status (KRT8, KRT18, KRT19, CRABP2, MUC1). This cluster was overexpressed in group I as compared with group II. Variation in the expression of ESR1 mRNA correlated well with the IHC ER status of samples (P ¼ 0.001, w 2 test between the negative or positive IHC status and the mRNA status defined as above or under the median expression level across samples). The similarity of this cluster with the previously reported luminal gene cluster (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Bertucci et al., 2004b) and its expression in many ERpositive cell lines suggested that group I cell lines were luminal.
The other major cluster (2.381 genes, designated basal cluster; orange bar in Figure 1a ) was overexpressed in group II as compared with group I. As shown in the gene dendrogram (Figure 1a) , it included several subclusters. One of them (391 genes, designated basalrestricted cluster; red bar in Figures 1a-c) was very similar to the previously reported basal gene cluster (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Bertucci et al., 2004b) , and included several cytokeratins (KRT4, 5, 6A, 6B, 13, 14, 15, 16; 17) , integrins (ITGA6, ITGB4, ITGB6), and other genes (LAMB3, LAMC2, TRIM29, S100A2, SLPI, ANXA8, COL17A1, BNC1). Another subcluster (792 genes, designated mesenchymal cluster; brown bar in Figures 1a-c) , designated mesenchymal cluster, included several genes encoding proteins with roles in the remodelling of the extracellular matrix: collagens (COL3A1, COL6A1, COL8A1, COL6A2, COL6A3), proteases (MMP2, MMP14, TIMP1, CTSC, PLAU, PLAUR, SERPINE1, SER-PINE2), and others such as VIM, SPARC, FN1, FBN1, HAS2, PRG1. This cluster was strongly overexpressed in Mmab, mouse monoclonal antibody; Rpab, rabbit polyclonal antibody; DTRS, Dako target retrieval solution.
Expression profiling of breast cell lines E Charafe-Jauffret et al the two cell lines known as mesenchymal-like, MDA-MB-231 and Hs578T, as well as SK-BR-7 and MDA-MB-157, overexpressed in other cell lines from group II, and underexpressed in cell lines from group I. Such results suggested that the mesenchymal molecular signature is shared by basal and mesenchymal cell phenotypes. Thus, the basal phenotype is a mixture of mesenchymal and 'basal-restricted' phenotypes. An ERBB2-related cluster (pink bar) was overexpressed in BCL known to have amplification of ERBB2. It included ERBB2, GRB7, PERLD1, STARD3, and C17ORF37, all of which map to chromosomal region 17q12 and belong to the ERBB2 gene expression signature (Bertucci et al., 2004a) . Expression of this cluster correlated with the IHC ERBB2 status of samples. It was overexpressed mostly in group I BCL, which included more ERBB2-positive cell lines than group II (P ¼ 0.008, Fisher's exact test).
Molecular subtypes of breast cell lines
The agreement between our data and previously described luminal, basal and mesenchymal gene clusters, and BCL subtypes (Ross and Perou, 2001 ) suggest the Expression profiling of breast cell lines E Charafe-Jauffret et al validity of our results. To confirm the subtypes of the profiled cell lines, we directly confronted our data with those of Ross and Perou (2001) . These authors have identified three molecular subtypes in BCL (luminallike, basal-like and mesenchymal-like) from the expression patterns of an 'intrinsic gene set' (B500 genes) used by Sorlie et al. This set defined five subtypes in breast cancer samples (Sorlie et al., 2001) . Of this 500-gene set, 364 overlapped with our 15,293 filtered genes. Hierarchical clustering of the available RNA expression data for these 364 common genes in the 24 cell lines from Ross and Perou still discriminated the same three subtypes (Supplementary Figure A) , suggesting that the 364-gene set was sufficient to identify BCL subtypes. Using the 364-gene set, we defined a representative expression profile for each subtype -thereafter designated centroid -among the 24 Ross and Perou samples. Samples from each centroid were selected based on the expression pattern of the luminal, basal and mesenchymal gene clusters respectively, and by selecting cell lines with the highest correlation with each other within the subtype (Supplementary Figure B) . We found (data not shown) six samples of luminal (correlation superior to 0.50), seven of basal (correlation superior to 0.56) and seven of mesenchymal (correlation superior to 0.40) subtype, in perfect concordance with the subtypes previously defined (Ross and Perou, 2001 ). The centroid expression for each of the three subtypes was calculated as the average expression for each of the 364 genes in the corresponding samples. We then measured the correlation of each of our 31 cell lines with each centroid: 15 were closer to luminal centroid (SK-BR-3, SUM-52, ZR-75-30, T47D, MCF-7, MDA-MB-453, UACC-812, ZR-75-1, CAMA-1, HCC1500, MDA-MB-134, BT-483, BT-474, MDA-MB-175, S68), eight to basal centroid (SUM-225, HME-1, MCF-10A, 184B5, SUM-149, HCC38, HCC1937, BT-20) and four to mesenchymal centroid (SK-BR-7, MDA-MB-157, MDA-MB-231, Hs578T). Four cell lines (SUM-185, SUM-190, BrCa-MZ-01, HCC1954) displayed a correlation inferior to 0.15 with any centroid and were not attributed any subtype. As shown in the dendrogram in Figure 1b , the major subgrouping of cell lines based on global hierarchical clustering (15 293 genes) was in agreement with the subtype to which they were closer: group I included all luminal-like cell lines and group II included basal-like and mesenchymal-like cell lines.
Differential gene expression between luminal and basal-like subtypes
We then applied supervised analysis based on the 15293 genes to the three BCL subtypes defined above: luminallike (15 cell lines), basal-like (eight cell lines) and mesenchymal-like (four cell lines). We used a discriminating score combined with permutation tests to correct for multiple hypothesis testing. For each comparison, the significance threshold used produced fewer than 30 false positives and ensured that the number of genes selected by chance, given 100 iterative random permutations, never exceeded the number of identified discriminator genes.
We identified 1.233 genes as differentially expressed between the luminal-like and the basal-like cell lines. A total of 578 genes were overexpressed and 665 were underexpressed in luminal-like cell lines. They represented 828 characterized genes and 125 other sequences or ESTs (Supplementary Table 2 ). These 1.233 genes were used as a discriminator and the classification power of this signature was illustrated by classifying all 31 samples according to the correlation coefficient of their expression profile for these genes with the median profile of the luminal-like cell lines (Figure 2a) . A threshold of 0 (orange solid line in Figure 2a ) sorted the samples into two classes ('predicted luminal class', positive scores; 'predicted basal class', negative scores) that strongly correlated with the observed phenotype: all luminal-like cell lines classified in the 'predicted luminal class', and all basal-like cell lines in the 'predicted basal class' (Po0.001, Fisher's exact test). Although the four mesenchymal-like cell lines were not included in the supervised analysis, they were classified in the 'predicted basal class' by the luminal/basal signature.
We tested the validity of our procedure by the 'leaveone-out' cross-validation method (Golub et al., 1999) . Iteratively, one of the 23 samples was removed, and a multigene predictor was generated from the remaining samples: 96% of samples were correctly assigned by the predictors (only the luminal cell line S68, was incorrectly assigned as basal). Although the predictive gene set generated by each of the cross-validation loops was slightly different at each iteration, on average 91% of the genes of our signature were conserved.
Among the 655 overexpressed in the basal cell lines were genes coding for cytokeratins (KRT5, 6, 14, 17), tyrosine kinases (MET, EGFR, LYN) ERM protein moesin (MSN), transcription factor ETS1, transmembrane hyaluronate receptor CD44, CD10, caveolae proteins CAV1 and CAV2, glycosylphosphatidylinositol (GPI)-anchored proteins CD14, CD58, and CD59, annexins, metalloproteinases, and WNT pathway inhibitor secreted Frizzled related protein-1 (SFRP1). Genes overexpressed in luminal cell lines included ESR1 and associated genes: transcription factor GATA3, trefoil peptide genes TFF1 and TFF3, XBP1, PRLR, CCND1, the genes coding for microtubule-associatedprotein TAU (MAPT) and the luminal ER-associated marker keratin 19 (KRT19).
Mesenchymal subtype in breast cell lines A total of 1.309 genes were identified as discriminator between the luminal-like and the mesenchymal-like cell lines. In sharp contrast, only 227 were identified as discriminatory between the basal-like and the mesenchymal-like cell lines (Supplementary Tables 3 and 4 ). The 'leave-one-out' cross-validation method revealed that 95% of samples were correctly assigned by the luminal/ mesenchymal predictor (only MCF-7 was not) and 83% by the basal/mesenchymal predictor (only HCC38 and HME-1 were not), with, respectively, an average of 94
Expression profiling of breast cell lines E Charafe-Jauffret et al and 65% of the genes of our signature that were conserved. Mesenchymal vimentin (VIM) for example, was discriminately overexpressed in mesenchymal BCL as compared with luminal BCL. Few relevant genes, including CD99, FLNC, LOXL2, and CD24, were differentially expressed between basal and mesenchymal cell lines. Neuroectodermal differentiation factor CD99 has been associated with matrix-producing breast carcinoma (Walker and Carder, 2003) . Filamin C crosslinks actin filaments into orthogonal networks and participates in the anchoring of membrane proteins to the cytoskeleton. CD24 whose protein is used for selection of differentiated epithelial cells was downregulated in mesenchymal cell lines as compared to both basal and luminal cell lines.
Breast cell line subtyping at the protein level
We next validated the results at the protein level by IHC. To study the cell lines simultaneously and in identical conditions, we adapted the tissue microarray technique to cell lines and prepared a cell microarray (CMA). 26 of the 31 cell lines were included in a CMA. Figure 3 shows a coloured section of the CMA and examples of IHC staining for 10 proteins. Results are summarized in Table 2 . Immunostaining was heterogeneous between the cells of a same cell line. This has been reported in the literature, notably for cytokeratin and vimentin expression (Mobus et al., 1998a) . As expected, markers defined as luminal, such as CK19, were prominent in luminal cell lines. Basal cell lines expressed known (CK5, CD10, EGFR) and newly identified basal markers (CAV1, CD44, ETS1, MET, moesin). Hierarchical clustering based on the 10 proteins identified two groups of cell lines that were quite similar to the clustering based on corresponding transcriptional data (Figure 2b-c) . The left group expressed CK19 and GATA3. The right group, including nonmalignant and cancer cell lines expressed basal markers CK5/6, CD10, CD44, CAV1, EGFR, ETS1, MET, and moesin. Protein clustering confirmed the luminal and basal assignment of cell lines, except for the ERBB2-overexpressing BT-474. This cell line was luminal in RNA analysis but basal in protein analysis. Its pattern of expression was complex with a mix of classical luminal (progesterone receptor, MUC1, EMA, cytokeratins 8/18/19) and basal markers (ER negativity, EGFR expression, CD10). The heterogeneity of staining of cells of this cell line can explain the discrepancies between mRNA and protein levels.
Classification of breast tumour tissue samples
We investigated whether our luminal/basal 1.233-gene signature defined on cell lines also discriminated similar subtypes on tumour tissue samples. As test sample set, we used the expression data of 122 breast tissue samples (115 cancer and seven non-malignant tissues) profiled by Sorlie et al. (2003) 
Discussion
Cell lines are the most used models in breast cancer studies (Lacroix and Leclercq, 2004 
Molecular subtypes of breast cell lines
The 31 BCL displayed transcriptional heterogeneity, indicating the existence of distinct molecular subtypes. Immunostaining for the 10 markers in the non-luminal cell line MDA-MB-231. Note the membranous staining for CK19, CK5/6, EGFR, CD44. MET staining is both membranous and cytoplasmic. GATA3 displays a nuclear staining.
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The correlation between our data and published molecular profiles (Ross and Perou, 2001 ) assigned 15 cell lines as luminal, and 12 as nonluminal (eight as basal and four as mesenchymal). The transcriptional profile of eight out of our 31 profiled cell lines has been established for B8.000 genes (Ross and Perou, 2001) . In spite of differences in DNA microarray platforms, all these cell lines but one were correctly assigned to each luminal, basal or mesenchymal group, suggesting the validity and the reliability of both the expression data and the molecular classification. Notably, normal breast-derived cell lines MCF-10A and 184B5, and Hs578T and MDA-MB-231 expressed mostly basal and mesenchymal/stromal genes, respectively (Ross and Perou, 2001 Foulkes et al., 2004) . The results further suggest that molecular subtypes represent prominent biological processes overcoming possible variations in gene expression in cell lines grown in different settings (Nugoli et al., 2003) . We and others (Sorlie et al., 2001; Bertucci et al., 2004a) have found that ERBB2 tumours merged more with ERÀ tumours expressing strong basal/myoepithelial-like and normal-like signature than with luminal ER þ samples. Despite this, all except one ERBB2-overexpressing cell line were assigned as luminal. This may result from intrinsic differences between tumours and cell lines but may reflect a more biological substratum. Besides the luminal and basal subtypes, a new molecular type, called apocrine, has been recently described (Farmer et al., 2005) . This type is defined on the basis of the androgen receptor status. Interestingly, most ERBB2-amplified tumours are comprised in this apocrine group.
The mesenchymal subtype, which has not been identified in tumour samples, was close to the basal subtype, whatever the number of genes used for (Figure 2 ). Hs578T, which is derived from a carcinosarcoma, is representative of this subtype. Carcinosarcomas are rare and heterogeneous tumours with somewhat confusing terminology such as metaplastic carcinomas, sarcomatoid carcinomas, or spindle cell carcinomas. They express basal and myoepithelial markers (Leibl et al., 2005) and may be key tumours for understanding epithelial-to-mesenchymal transition (EMT). They may represent the extreme end point of basal differentiation. Some markers expressed in carcinosarcomas (Leibl et al., 2005) were identified as basal or mesenchymal markers in our study (CK5/KRT5, CK14/KRT14, CK17/KRT17, CD10/MME, myoepithelial marker 14-3-3d/stratifin, p63/TP73L, Maspin/serpinB5, S-100/S100A2, vimentin/VIM). Carcinosarcomas represent less than 1% of breast carcinomas, and the absence of identification of the mesenchymal subtype in breast tumours could reflect this rare occurrence. Alternatively, serum adjunction in culture may induce a strong EMT and modify the phenotype of some cell lines that become mesenchymal-like, whereas others remain with their original basal or luminal characteristics. Several genes overexpressed in mesenchymal cell lines (e.g. LOXL2) belong to a gene expression signature of fibroblast serum response (Chang et al., 2004) , which could be in support of this hypothesis.
'Basalness': definition of a 'basal' signature with a potential functional module Supervised analysis identified 1.233 genes differentially expressed between luminal and basal cell lines. Overexpressed genes included genes encoding reported basal markers such as KRT5, KRT6, KRT14, KRT17, CD10, EGFR, ANXA8, SLPI, TRIM29, CRYAB, LAMA3, LAMC2 (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Bertucci et al., 2004b) . This molecular signature may represent a bar code signature of the luminal/basal phenotype. Whether the discriminator genes are causative or even predictive of the phenotype in a biological sense or reflect another associated phenomenon remain to be explored. From the vantage point of gaining mechanistic insight into the biology of breast cancer, these results should be regarded as hypothesis-generating only. However, it was encouraging to see that many of the discriminator genes are involved in the same pathways of adhesion, invasiveness and cell motility, and might be related to the poor prognosis of basal tumours. Some of them are located in the same chromosomal region such as MET, CAV1 and CAV2, and could represent a specific 7q31 amplicon for basal subtype if their co-overexpression were to be linked to gene amplification. The MET gene encodes the tyrosine kinase receptor (RTK) for hepatocyte growth factor (HGF)/Scatter Factor (SF) involved in various cellular processes (Trusolino and Comoglio, 2002) and in cancer (Parr et al., 2004; Lengyel et al., 2005; Welm et al., 2005) . CD44 is a cell adhesion molecule and hyaluronate receptor whose overexpression has been associated to lymph node invasion (Bertucci et al., 2000) and metastasis (Martin et al., 2003) . ERM (ezrin, radixin, moesin) family plays a role in CD44 membrane anchoring and is implicated in cell motility (Nakamura et al., 2000) . Moesin expression has also been associated with ER-negative breast cancer phenotype (Carmeci et al., 1998) and is also part of a gene expression signature associated with cell motility and invasion (Condeelis et al., 2005) . A CD44 variant (CD44v6) sensitizes MET to HGF stimulation (Bertotti and Comoglio, 2003) . MET and CD44 can interact with moesin to influence cell motility. ETS1 is a downstream target of the HGF/SF pathway. Reciprocally, ETS1 acts as transcriptional factor for the MET gene (Paumelle et al., 2002) . Several genes encoding proteins of the motility machinery, that is, cofilin, ARP2/3 pathways and RHO-GTPase interacting proteins, were also upregulated in basal cell lines.
Caveolin genes CAV1 and CAV2 were overexpressed in basal cell lines. Caveolae are invaginations of the plasma membrane that serve both to compartmentalize and regulate signalling (Razandi et al., 2002; Navarro et al., 2004; Williams and Lisanti, 2005) . Caveolins are key molecules for cell migration. Caveolins and annexins play a role in plasma membrane dynamics and cellular trafficking. Specific membrane type (MT)-matrix metalloproteinases (MMPs) such as MMP14, associated with invasive potential (Zhao et al., 2004) were overexpressed in basal cell lines. Several genes encoding GPI-anchored proteins (CD58, CD59, NT5E/ CD73, CD109, PRNP) (Sangiorgio et al., 2004) and other signalling proteins (PTRF, RRAS2, ARPC2) (Sprenger et al., 2004) were overexpressed in basal cell lines, in agreement with the presence of these proteins in caveolae.
The luminal signature included many genes associated with oestrogen signalling and/or sensitivity (ESR1, GATA3, XBP1, TFF1, TFF3) and was completely in agreement with published data (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Bertucci et al., 2004b) . It also contained the ER-responsive gene coding for NHE-RF/EBP50/SLC9A3R1 protein, which inhibits cell migration by scaffolding ERM proteins and regulating their link with the actin cytoskeleton (Ediger et al., 2002) . In perfect agreement, this gene is overexpressed in non-invasive vs invasive BCL (Schindelmann et al., 2002) .
To our knowledge, this study is the first one to classify so many BCL using whole-genomic expression data and validation at the protein level. We defined a basal signature from cell line analysis and isolated potential interesting markers. These markers have now to be tested in larger series of tumours to determine if they have a prognostic impact, and if their definition of basalness is better than that of currently used markers such as basal cytokeratins, for example. Our results on the classification of a published set of samples suggest that our new identified markers could indeed be used for tumour classification. We identified a potential functional module associated with basalness and potentially with the caveosome, and seemingly involved in cell migration. A search for inhibitors of this module could Expression profiling of breast cell lines E Charafe-Jauffret et al lead to the identification of drugs able to control tumour invasiveness and metastasis. Most of the markers are activated by phoshorylation and some belong to the RTK family. They may represent therapeutic targets in the future since anti-EGFR are commercially available and anti-MET are in preclinical stage studies (Christensen et al., 2005) .
Material and methods
Breast tumour-derived and normal breast-derived cell lines A total of 31 BCL were analysed: BT-20, BT-474, BT-483, CAMA-1, HCC38, HCC1500, HCC1937 (Tomlinson et al., 1998) , HCC1954, HME-1, carcinosarcoma-derived Hs578T (Hackett et al., 1977) , MCF-7, MCF10A, MDA-MB-134, MDA-MB-157, MDA-MB-175, MDA-MB-231, MDA-MB-453, SK-BR-3, SK-BR-7, T47D, UACC-812, ZR-75-1, ZR-75-30 (http://www.atcc.org/), HMEC-derived 184B5 (ATCC, http://www.atcc.org/), BrCa-MZ-01 (Mobus et al., 1998b) , SUM-52, SUM-149, SUM-185, SUM-190, SUM-225 (Ethier et al., 1993; Forozan et al., 1999) ; http://www.cancer.med.umich.edu/breast_cell/production), and a recently established breast tumour cell line called S68, derived from a pleural effusion of an invasive ductal carcinoma (a kind gift from V. Catros, Cell Biology Department, CHU Rennes, France). All cell lines are derived from carcinomas except MCF-10A, which is derived from a fibrocystic disease, and HME-1 and 184B5, which represent normal mammary tissue. The cell lines were grown using the recommended culture conditions.
RNA extraction
Total RNA was extracted from frozen cell lines as previously described (Theillet et al., 1993) . RNA integrity was controlled by denaturing formaldehyde agarose gel electrophoresis and by micro-analysis (Agilent Bioanalyzer, Palo Alto, CA, USA).
Gene expression profiling RNA expression profiling was done with Affymetrix U133 Plus 2.0 human oligonucleotide microarrays. Microarrays represented over 47.000 transcripts and variants from human genes. cRNA preparations, hybridizations, washes and detection were done as recommended by the supplier (www.Affymetrix.com). Briefly, for each sample, synthesis of the firststrand cDNA was done from 3 mg total RNA by T7-oligo(dT) priming, followed by second-strand cDNA synthesis. After purification of cDNA, an in vitro transcription combined with amplification of cRNA was used to generate the cRNA containing biotinylated pseudo-uridine, which was then purified, quantified and chemically fragmented at 951C for 35 min. Fragmented biotinylated cRNA was hybridized in 200 ml hybridization buffer at 451C for 16 h to microarrays. Automated washes of microarrays and staining with streptavidin-phycoerythrin were done according to the manufacturer's instructions. Double signal amplification was done by biotinylated anti-streptavidin antibody with goat-IgG blocking antibody. Signal detection was done with Affymetrix GeneArray scanner and quantification with Affymetrix GCOS software.
All hybridization images were inspected for artefacts. Expression data was then analyzed by the RMA (Robust Multichip Average) method in R using Bioconductor and associated packages (Irizarry et al., 2003) . RMA performed the background adjustment, the quantile normalization and finally the summarization of 11 oligonucleotides per gene. Filtering process removed from analysis the genes with low expression change across all samples, as defined by standard deviation inferior to 100 for the expression values superior to two-fold the median expression level, retaining 15.293 genes. This excluded genes with low and poorly measured expression and with low expression variation. All data was then log 2 -transformed and analysed by a combination of unsupervised and supervised methods. Unsupervised hierarchical clustering of expression data was done with the Cluster program (Eisen et al., 1998) using Pearson correlation as similarity metric and centroid linkage clustering. Results were displayed using the TreeView program (Eisen et al., 1998) . Supervised analysis was applied to the 15.293 genes and cell lines to identify and rank genes (molecular signature) that discriminate between two relevant subgroups of cell lines (luminal-like vs basal-like, luminal-like vs mesenchymal-like, and mesenchymal-like vs basal-like). A discriminating score (DS) was calculated for each gene (Golub et al., 1999) as DS ¼ (M1ÀM2)/(S1 þ S2) where M1 and S1 respectively represent mean and standard deviation of expression levels of the gene in subgroup 1, and M2 and S2 in subgroup 2. Because of multiple hypothesis testing, confidence levels were estimated by 100 iterative random permutations of samples as previously described (Golub et al., 1999) with a false-positive rate of 1/1.000 (less than 30 false positives). We also tested whether the number of differentially expressed genes exceeded that which might arise by chance. In this test, the distribution of numbers of differentially expressed genes generated by repeatedly permutating (100 times) the labels of the samples and recalculating the DS at the specified level of significance was compared with the observed number of significantly differentially expressed genes (Chang et al., 2003) . Once identified, the classification power of the discriminator signature was illustrated by classifying samples according to the correlation coefficient of their expression profile with the median profile of the subgroup 1 samples. A 'leave-one-out' procedure (Golub et al., 1999) was applied to estimate the accuracy of prediction of the identified molecular signatures and the validity of supervised analysis. Iteratively, one of the samples was removed, and a list of discriminator genes was generated from the remaining samples according to the procedure described above. The 'leave-one-out' sample was then classified by using this predictor and the procedure described above. The process was repeated for each of the samples and the rate of correct classifications was calculated.
Cell microarrays
Paraffin-embedded cells from cell lines are mostly scattered and immunostaining could not be easy to interpret. To circumvent this problem, we built cell microarray (CMA). In all, 26 out of the 31 cell lines were processed with this method were not included). Briefly, 3-6 Â 10 7 cultured cells were resuspended and fixed overnight in PBS containing 3.8% formaldehyde. Fixed cells were centrifuged at 1.800 r.p.m. for 10 min. The pellet was resuspended in 1 ml of 1% low melting point agarose (LMP Agarose European Pack, Invitrogen) at 371C. This suspension was transferred into a 2 ml syringe and immediately placed for 10 min on ice. The terminal end of the syringe was cut and 0.5 ml agarose cylinders were fixed, at least 3 h, in ice-cooled formalin-alcohol fixative. Cylinders were then processed in automated tissue processor (ASP300, LEICA) for an overnight run. The processed cylinders were then paraffin-embedded. CMA was prepared as for tissue microarrays with some modifications (Ginestier et al., 2002) . For each of these 26-cell pellet paraffin blocks, a core cylinder Expression profiling of breast cell lines E Charafe-Jauffret et al with a diameter of 2 mm was punched and deposited into a recipient paraffin block using a specifying arraying device (Beecher Instruments, Silver Spring, MD). The 5-mm sections of the CMA block were used for conventional immunohistochemistry (IHC) after transfer to glass slides.
Antibodies
A total of 10 proteins were tested. The choice was based on DNA arrays data and availability and suitability of a corresponding antibody for paraffin-embedded samples. The characteristics are listed in Table 1 . They included transcription factor GATA3, differentiation markers previously known and validated in our study (CK19, CK5/6, CD10, tyrosine kinase receptors (EGFR, MET), the anchorage molecule CD44 and MET transcription factor ETS1, the ERM protein Moesin (MSN) and the caveolae protein CAV1.
Immunohistochemistry IHC was done on 5-mm sections of tissue fixed in alcohol formalin for 24 h and embedded in paraffin as previously described (Ginestier et al., 2002) using Dako LSAB R 2 Kit in the autoimmunostainer (Dako Autostainer). Details are given in Table 1 . The dilution of each antibody was established on the basis of negative and positive controls and staining with a range of dilutions. For each antibody, the selected titer was in the linear range and allowed the extinction of the negative control and the persistence of the positive control. If signal-tobackground ratio was not acceptable for the dilution, the pretreatment or experimental conditions were readjusted. After staining, slides were evaluated by two pathologists (E.C.J, J.J.). Results were scored by semiquantitative method as follows: 0 for no positive cell, 1 for 1-5% of positive cells, 2 for 6-50% of positive cells, 3 for 51-90% of positive cells, and 4 for 91-100% of positive cells. For each cell line, the mean of the score of a minimum of two core biopsies on two different slides was calculated. Discrepancies were resolved under the multiheaded microscope. Hierarchical clustering and display of IHC data (Cluster and TreeView programs) were based on IHC scores log 2 -transformed and standardized by the corresponding protein mean and standard deviation.
Statistical analysis
Statistical analyses were done using the SPSS software (version 10.0.5). Correlations between sample groups and histological parameters were calculated with the Fisher's exact test. A P-value o0.05 was considered significant.
